These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

223 related articles for article (PubMed ID: 37672954)

  • 21. Relapsed/Refractory Mantle Cell Lymphoma: Beyond BTK Inhibitors.
    Burkart M; Karmali R
    J Pers Med; 2022 Mar; 12(3):. PubMed ID: 35330376
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Chimeric antigen receptor T-cell therapy: a promising treatment modality for relapsed/refractory mantle cell lymphoma.
    Li P; Dong N; Zeng Y; Liu J; Tang X; Wang J; Zhang W; Ye S; Zhou L; Chang AH; Liang A
    Front Med; 2020 Dec; 14(6):811-815. PubMed ID: 32651937
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The mTOR kinase inhibitor everolimus synergistically enhances the anti-tumor effect of the Bruton's tyrosine kinase (BTK) inhibitor PLS-123 on Mantle cell lymphoma.
    Li J; Wang X; Xie Y; Ying Z; Liu W; Ping L; Zhang C; Pan Z; Ding N; Song Y; Zhu J
    Int J Cancer; 2018 Jan; 142(1):202-213. PubMed ID: 28905990
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Brexucabtagene autoleucel: a breakthrough in the treatment of mantle cell lymphoma.
    Deshpande A; Wang Y; Munoz J; Jain P
    Drugs Today (Barc); 2022 Jun; 58(6):283-298. PubMed ID: 35670706
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Ibrutinib: a review of its use in patients with mantle cell lymphoma or chronic lymphocytic leukaemia.
    Kim ES; Dhillon S
    Drugs; 2015 May; 75(7):769-76. PubMed ID: 25802231
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Ibrutinib for mantle cell lymphoma.
    Tucker DL; Rule SA
    Future Oncol; 2016 Feb; 12(4):477-91. PubMed ID: 26759179
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Combating relapsed and refractory Mantle cell lymphoma with novel therapeutic armamentarium: Recent advances and clinical prospects.
    Raghani NR; Shah DD; Shah TS; Chorawala MR; Patel RB
    Crit Rev Oncol Hematol; 2023 Oct; 190():104085. PubMed ID: 37536448
    [TBL] [Abstract][Full Text] [Related]  

  • 28. NCCN GuidelinesĀ® Insights: B-Cell Lymphomas, Version 6.2023.
    Zelenetz AD; Gordon LI; Abramson JS; Advani RH; Andreadis B; Bartlett NL; Budde LE; Caimi PF; Chang JE; Christian B; DeVos S; Dholaria B; Fayad LE; Habermann TM; Hamid MS; Hernandez-Ilizaliturri F; Hu B; Kaminski MS; Karimi Y; Kelsey CR; King R; Krivacic S; LaCasce AS; Lim M; Messmer M; Narkhede M; Rabinovitch R; Ramakrishnan P; Reid E; Roberts KB; Saeed H; Smith SD; Svoboda J; Swinnen LJ; Tuscano J; Vose JM; Dwyer MA; Sundar H
    J Natl Compr Canc Netw; 2023 Nov; 21(11):1118-1131. PubMed ID: 37935098
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Novel agents in mantle cell lymphoma.
    Kumar A
    Curr Oncol Rep; 2015 Aug; 17(8):34. PubMed ID: 26045130
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Novel therapies for relapsed/refractory mantle cell lymphoma.
    Arora PC; Portell CA
    Best Pract Res Clin Haematol; 2018 Mar; 31(1):105-113. PubMed ID: 29452660
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Targeting the immune microenvironment in mantle cell lymphoma: implications for current and emerging therapies.
    Qualls D; Kumar A; Epstein-Peterson ZD
    Leuk Lymphoma; 2022 Nov; 63(11):2515-2527. PubMed ID: 35704674
    [TBL] [Abstract][Full Text] [Related]  

  • 32. New Directions for Mantle Cell Lymphoma in 2022.
    Kumar A; Eyre TA; Lewis KL; Thompson MC; Cheah CY
    Am Soc Clin Oncol Educ Book; 2022 Apr; 42():1-15. PubMed ID: 35561299
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Bruton tyrosine kinase inhibitors for the treatment of mantle cell lymphoma: review of current evidence and future directions.
    Bond DA; Alinari L; Maddocks K
    Clin Adv Hematol Oncol; 2019 Apr; 17(4):223-233. PubMed ID: 31188814
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Ibrutinib for the treatment of mantle cell lymphoma.
    Shah N; Hutchinson C; Rule S
    Expert Rev Hematol; 2014 Oct; 7(5):521-31. PubMed ID: 25158606
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Management of relapsed/refractory mantle cell lymphoma.
    Alzahrani M; Villa D
    Leuk Lymphoma; 2024 Aug; 65(8):1044-1054. PubMed ID: 38635491
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Relapsed Mantle Cell Lymphoma: Current Management, Recent Progress, and Future Directions.
    Bond DA; Martin P; Maddocks KJ
    J Clin Med; 2021 Mar; 10(6):. PubMed ID: 33799484
    [TBL] [Abstract][Full Text] [Related]  

  • 37. New and emerging Bruton tyrosine kinase inhibitors for treating mantle cell lymphoma - where do they fit in?
    Rule S; Chen RW
    Expert Rev Hematol; 2018 Sep; 11(9):749-756. PubMed ID: 30052472
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The Novel Therapeutic Landscape for Relapsed/Refractory Diffuse Large B Cell Lymphoma.
    Nuvvula S; Dahiya S; Patel SA
    Clin Lymphoma Myeloma Leuk; 2022 Jun; 22(6):362-372. PubMed ID: 34922844
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Challenges and solutions to superior chimeric antigen receptor-T design and deployment for B-cell lymphomas.
    Gao J; Dahiya S; Patel SA
    Br J Haematol; 2023 Oct; 203(2):161-168. PubMed ID: 37488074
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Chimeric antigen receptor (CAR) T-cell treatment for mantle cell lymphoma (MCL).
    Tbakhi B; Reagan PM
    Ther Adv Hematol; 2022; 13():20406207221080738. PubMed ID: 35237395
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.